[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnancy-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnancy-loss":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,68,94,124,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":43,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100345304","fetal-electrophysiologic-abnormalities-in-high-risk-pregnancies-associated-with-fetal-demise-100345304",false,"NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise","Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise","Inclusion Criteria:\n\n* Current pregnancy complicated by one of the five diagnostic categories\n\n  * prior unexplained Stillbirth at\u002Fafter 20 weeks gestation\n  * fetal major congenital heart defect\n  * fetal hydrops\n  * fetal gastroschisis\n  * monochorionic twin pregnancy\n* Subject must be 18 years of age or older\n* Subject must be English speaking and must be able to read and sign the consent form in English\n* Subject must be able to recline comfortably for 1-3 hours\n* Subject must be willing to complete all three procedures (fMCG, fMCG, nECG) as per protocol, unless medically unable\n* Subject must be willing to allow us to review her and her infants prenatal, deliver, and post-natal records to verify diagnosis, and clinical findings.\n\nExclusion Criteria:\n\n* Severe claustrophobia not reduced by taking breaks, or by having the light on, or by having someone in the room with them.\n* Active labor\n* Acute illness\n* Unable to recline comfortably with a pillow for more than 1-3 hours (assuming some breaks are provided)\n* Weight over 450 lbs\n* An electric stimulation device (TENS unit, pacemaker, or nerve stimulator) that could produce electric or magnetic noise.\n\n  * Note that the Tristan 624 Magnetometer does not pose a risk to the subject's device, (since fMCG does not produce any energy or magnetism), but stimulators themselves can cause interference for our recordings. Some devices may still qualify, and discussion with study nurse may be useful if subject has a pacemaker or similar device.\n\nThe subject will have a single 2-3 hour fetal magnetocardiogram at approximately 20 and 27 weeks GA, and again, if medical condition allows, between 30 and 37 weeks GA, then her infant will have an ECG between 0 and 4 weeks of age. Subjects will be paid a nominal fee for their participation each time, as well as transportation reimbursement if \\>25 miles. For subjects traveling a long distance, the ECG may be performed locally or at home.","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"High Risk Pregnancy","Congenital Heart Disease","Fetal Hydrops","Twin Monochorionic Monoamniotic Placenta","Gastroschisis","Fetal Demise","Stillbirth","Fetal Arrhythmia","Long QT Syndrome","Intrauterine Fetal Death","Sudden Infant Death","Pregnancy Loss","Twin Twin Transfusion Syndrome","Birth Defect","Fetal Cardiac Anomaly","Fetal Cardiac Disorder","Fetal Death","Brugada Syndrome","Fetal Tachycardia",[44,30,45,46,47,24,48,49,50,51,52,53,54],"Fetal Magnetocardiography","Intrauterine Fetal Demise","Fetal Heart Rate Variability","Fetal Arrhythmias","Pregnancy","Fetal Anomaly","Fetal Echocardiography","Non-Stress Testing","New Technology","Birth Defects","Fetal Research","RECRUITING","2026-03-02",{"date":58,"type":59},"2026-03-04","ACTUAL",{"date":61,"type":59},"2018-07-01",{"date":63,"type":20},"2028-11-30",{"name":65,"class":66},"Medical College of Wisconsin","OTHER",2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100547454","phase-3-apple-aspirin-to-prevent-pregnancy-loss-and-preeclampsia-100547454","NCT06408181","APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia","APPLE","Inclusion Criteria\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Ability to take oral medication and be willing to adhere to the prescribed aspirin regimen.\n4. Patients with a gestation less than or equal to 6 weeks, 6 days (as determined by patient record of LMP or ART date).\n5. Patients between 18-45-year old who have one or more risk factors for preeclampsia and\u002For pregnancy loss, including:\n\n   1. preeclampsia in a previous pregnancy,\n   2. gestational diabetes in a previous pregnancy,\n   3. any documentation of fetal growth restriction or low birth weight in a prior pregnancy,\n   4. preterm birth in a previous pregnancy,\n   5. known multifetal gestation at enrollment,\n   6. chronic hypertension,\n   7. pregestational diabetes,\n   8. kidney disease,\n   9. systemic lupus erythematosus,\n   10. nulliparity,\n   11. pre-pregnancy body mass index \\>30,\n   12. family history of preeclampsia (i.e., mother or sister),\n   13. Black persons (due to social, not biological reasons),\n   14. Maternal age 35 years or older,\n   15. lower income (will be determined by qualification of public health insurance),\n   16. conceived with fertility treatment (including in vitro fertilization, ovulation induction, or intrauterine insemination),\n   17. history of one or more prior pregnancy losses \\\u003C20 weeks gestation,\n   18. history of stillbirth in a prior pregnancy,\n   19. An interval of greater than 10 years since the last pregnancy.\n\nExclusion Criteria\n\n1. Known allergies to aspirin or non-steroidal anti-inflammatory agents (NSAID);\n2. Clinical indication for anticoagulant therapy, including prior or current thrombosis, antiphospholipid syndrome, or known major thrombophilia;\n3. Clinical indication for chronic use of NSAIDS during pregnancy;\n4. Medical contraindication to aspirin therapy, including untreated uncontrolled asthma, untreated symptomatic nasal polyps, bleeding disorders, or history of gastrointestinal ulcer.\n5. Patients with pelvic pain or bleeding who require urgent care (i.e., active vaginal bleeding greater than or equal to expected menses, open cervical os suggesting active miscarriage or severe pain requiring evaluation for ectopic pregnancy)","45 Years",{"count":77,"type":20},1150,"INTERVENTIONAL",[80],"PHASE3","The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are:\n\nDoes this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.",[83,35],"Pre-Eclampsia","2026-01-16",{"date":86,"type":59},"2026-01-20",{"date":88,"type":59},"2024-06-12",{"date":90,"type":20},"2029-06",{"name":92,"class":66},"University of Pennsylvania",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":78,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":93},"100618574","individualized-grief-support-with-swanson-model-100618574","NCT07333391","Individualized Grief Support With Swanson Model","Evaluation of the Effectiveness of Individualized Grief Support Based on the Swanson Caring Model in Women Experiencing Pregnancy Loss","Inclusion Criteria:\n\n* Aged 18 years and above,\n* Literate,\n* Able to understand and speak Turkish,\n* Desired and planned pregnancies\n* No diagnosed psychiatric illness,\n* No hearing or mental disabilit\n\nExclusion Criteria:\n\n* Women who experienced pregnancy loss after infertility treatment\n* Women who received psychological support during the process\n* Women who scored very high on the DAS scale\n* Women who withdrew from the study at any stage\n* Women who did not complete the data collection forms will be excluded from the study.",true,"50 Years",{"count":104,"type":20},48,[106],"NA","This study aims to examine the effects of individualized grief support for women experiencing pregnancy loss. The research, which will be conducted at Süleyman Demirel University, is a mixed-method design and includes both phenomenological qualitative analysis and randomized controlled quantitative trials. The sample will include 48 women; those with severe depression will be excluded. Quantitative data will be analyzed using SPSS, and qualitative data will be analyzed using content analysis.",[35,109],"Grief",[35,109,111,112,113],"İndividualized care","Swanson model","Psychosocial Support","NOT_YET_RECRUITING","2025-12-30",{"date":117,"type":59},"2026-01-12",{"date":119,"type":20},"2026-02-01",{"date":121,"type":20},"2026-07-30",{"name":123,"class":66},"Suleyman Demirel University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":93},"100584793","placental-organoids-development-application-in-the-study-of-the-human-reproduction-pathophysiology-100584793","NCT06893978","Placental Organoids Development: Application in the Study of the Human Reproduction Pathophysiology.","PLORG","Inclusion Criteria:\n\n* Women with uncomplicated normal term pregnancy undergoing elective cesarean section for previous uterine surgery or breech presentation of the fetus;\n* Patients with retained abortion and history of recurrent abortion sine causa at the end of the work-up of investigations performed according to ESHRE guidelines, undergoing revision of the uterine cavity;\n* Patients diagnosed with preeclampsia, defined in accordance with the definitions of ISSHP, undergoing cesarean section;\n* Patients with preterm onset, before 37 weeks gestational age, of spontaneous labor, undergoing cesarean section in labor for low weight or abnormal fetal presentation.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Chronic infection with HIV or HCV;\n* Ongoing malignant neoplasms;\n* Multiple pregnancies;\n* Inability to provide informed informed consent.",{"count":132,"type":20},20,"Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis and placental secretomics.",[135,35,136,137],"Preeclampsia","Preterm Birth","Healthy","2025-05-14",{"date":140,"type":59},"2025-05-20",{"date":140,"type":20},{"date":143,"type":20},"2027-11",{"name":145,"class":66},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":101,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":156,"studyType":21,"phases":4,"briefSummary":157,"conditions":158,"keywords":164,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":67},"100449036","impact-of-the-microbiome-on-time-to-pregnancy-and-pregnancy-outcomes-in-fertile-women-attempting-to-conceive-100449036","NCT05127252","Impact of the Microbiome on Time to Pregnancy and Pregnancy Outcomes in Fertile Women Attempting to Conceive","SweBioFertil","Inclusion Criteria:\n\n* Women with a previous live birth in the past 5 years and planning a new pregnancy with the same male partner.\n* 18-40 years of age\n* Swedish personal identity number and a Swedish address (to send a sampling self-kit)\n* Sufficient understanding of spoken and written Swedish or English to provide informed consent and complete the web-based questionnaire.\n\nExclusion Criteria:\n\n* Women who do not have a child yet and plan to cease their contraception.","40 Years",{"count":155,"type":20},500,"2 Years","This study aims to investigate the microbiome of women with previously proven fertility who plan to become pregnant.",[159,160,35,161,162,163],"Pregnancy Complications","Contraception","Fertility","Microbial Colonization","Metabolome",[165,166,167,168],"cohort","fertility","microbiome","microbiota","2023-05-26",{"date":171,"type":59},"2023-05-30",{"date":173,"type":59},"2023-04-10",{"date":175,"type":20},"2026-12-30",{"name":177,"class":66},"Karolinska Institutet"]